Safety indications in mouse models treated with full doses of MEK inhibitors and SHP099

Bookmark and Share
Published: 25 Apr 2018
Views: 4198
Rating:
Save
Dr Carmine Fedele - Laura and Isaac Perlmutter Cancer Center at New York University Langone Medical, New York, USA

Dr Fedele speaks with ecancer at AACR 2018 about adding an SHP2 inhibitor to MEK targeted therapy to overcome drug resistance.

He describes results from in vitro and in vivo cancer models, with significant and cancer specific toxicity in mice model treated with full doses of MEK inhibitors and SHP099